Direct reprogramming of induced neural progenitors: A new promising strategy for AD treatment

Siqiang Lai; Min Zhang; Dongsheng Xu; Yiying Zhang; Lisha Qiu; Changhai Tian; Jialin Charlie Zheng

doi:10.1186/s40035-015-0028-y

Direct reprogramming of induced neural progenitors: A new promising strategy for AD treatment

Siqiang Lai
, Min Zhang
, Dongsheng Xu
, Yiying Zhang
, Lisha Qiu
, Changhai Tian
, Jialin Charlie Zheng

Research output: Contribution to journal › Review article › peer-review

11 Scopus citations

Abstract

Alzheimer's disease (AD) is a prominent form of dementia, characterized by aggregation of the amyloid β-peptide (Aβ) plaques and neurofibrillary tangles, loss of synapses and neurons, and degeneration of cognitive functions. Currently, although a variety of medications can relieve some of the symptoms, there is no cure for AD. Recent breakthroughs in the stem cell field provide promising strategies for AD treatment. Stem cells including embryonic stem cells (ESCs), neural stem cells (NSCs), mesenchymal stem cells (MSCs), and induced pluripotent stem cells (iPSCs) are potentials for AD treatment. However, the limitation of cell sources, safety issues, and ethical issues restrict their applications in AD. Recently, the direct reprogramming of induced neural progenitor cells (iNPCs) has shed light on the treatment of AD. In this review, we will discuss the latest progress, challenges, and potential applications of direct reprogramming in AD treatment.

Original language	English
Article number	7
Journal	Translational Neurodegeneration
Volume	4
Issue number	1
DOIs	https://doi.org/10.1186/s40035-015-0028-y
State	Published - Apr 18 2015

Bibliographical note

Publisher Copyright:
© Lai et al.; licensee BioMed Central.

Funding

This work was partly supported by research grants by National Basic Research Program of China (973 Program Grant No. 2014CB965001), National Natural Science Foundation of China (#81271419), Innovative Research Groups of the National Natural Science Foundation of China (#81221001), and Joint Research Fund for Overseas Chinese, Hong Kong and Macao Young Scientists of the National Natural Science Foundation of China (#81329002); National Institutes of Health: R01 NS 41858–01, R01 NS 061642–01, P20 RR15635-01, the State of Nebraska, DHHS-LB606 Stem Cell 2009–10 (JZ), LB606 Stem Cell-2010-10 (CT). Julie Ditter, Lenal Bottoms, Johna Belling, Jaclyn Ostronic and Robin Taylor provided outstanding administrative and secretarial support.

Funders	Funder number
Joint Research Fund for Overseas Chinese, Hong Kong and Macao Young Scientists	81329002
National Institutes of Health (NIH)	R01 NS 061642–01, P20 RR15635-01, R01 NS 41858–01, LB606 Stem Cell-2010-10
National Natural Science Foundation of China (NSFC)	81221001, 81271419
National Key Basic Research and Development Program of China	2014CB965001

Keywords

Alzheimer's disease
Induced neural progenitor cells
Stem cell-based therapy

ASJC Scopus subject areas

Clinical Neurology
Cognitive Neuroscience
Cellular and Molecular Neuroscience

Access to Document

10.1186/s40035-015-0028-y

Cite this

@article{cb00761602184f479561bba6e96da677,

title = "Direct reprogramming of induced neural progenitors: A new promising strategy for AD treatment",

abstract = "Alzheimer's disease (AD) is a prominent form of dementia, characterized by aggregation of the amyloid β-peptide (Aβ) plaques and neurofibrillary tangles, loss of synapses and neurons, and degeneration of cognitive functions. Currently, although a variety of medications can relieve some of the symptoms, there is no cure for AD. Recent breakthroughs in the stem cell field provide promising strategies for AD treatment. Stem cells including embryonic stem cells (ESCs), neural stem cells (NSCs), mesenchymal stem cells (MSCs), and induced pluripotent stem cells (iPSCs) are potentials for AD treatment. However, the limitation of cell sources, safety issues, and ethical issues restrict their applications in AD. Recently, the direct reprogramming of induced neural progenitor cells (iNPCs) has shed light on the treatment of AD. In this review, we will discuss the latest progress, challenges, and potential applications of direct reprogramming in AD treatment.",

keywords = "Alzheimer's disease, Induced neural progenitor cells, Stem cell-based therapy",

author = "Siqiang Lai and Min Zhang and Dongsheng Xu and Yiying Zhang and Lisha Qiu and Changhai Tian and Zheng, \{Jialin Charlie\}",

note = "Publisher Copyright: {\textcopyright} Lai et al.; licensee BioMed Central.",

year = "2015",

month = apr,

day = "18",

doi = "10.1186/s40035-015-0028-y",

language = "English",

volume = "4",

number = "1",

}

TY - JOUR

T1 - Direct reprogramming of induced neural progenitors

T2 - A new promising strategy for AD treatment

AU - Lai, Siqiang

AU - Zhang, Min

AU - Xu, Dongsheng

AU - Zhang, Yiying

AU - Qiu, Lisha

AU - Tian, Changhai

AU - Zheng, Jialin Charlie

PY - 2015/4/18

Y1 - 2015/4/18

N2 - Alzheimer's disease (AD) is a prominent form of dementia, characterized by aggregation of the amyloid β-peptide (Aβ) plaques and neurofibrillary tangles, loss of synapses and neurons, and degeneration of cognitive functions. Currently, although a variety of medications can relieve some of the symptoms, there is no cure for AD. Recent breakthroughs in the stem cell field provide promising strategies for AD treatment. Stem cells including embryonic stem cells (ESCs), neural stem cells (NSCs), mesenchymal stem cells (MSCs), and induced pluripotent stem cells (iPSCs) are potentials for AD treatment. However, the limitation of cell sources, safety issues, and ethical issues restrict their applications in AD. Recently, the direct reprogramming of induced neural progenitor cells (iNPCs) has shed light on the treatment of AD. In this review, we will discuss the latest progress, challenges, and potential applications of direct reprogramming in AD treatment.

AB - Alzheimer's disease (AD) is a prominent form of dementia, characterized by aggregation of the amyloid β-peptide (Aβ) plaques and neurofibrillary tangles, loss of synapses and neurons, and degeneration of cognitive functions. Currently, although a variety of medications can relieve some of the symptoms, there is no cure for AD. Recent breakthroughs in the stem cell field provide promising strategies for AD treatment. Stem cells including embryonic stem cells (ESCs), neural stem cells (NSCs), mesenchymal stem cells (MSCs), and induced pluripotent stem cells (iPSCs) are potentials for AD treatment. However, the limitation of cell sources, safety issues, and ethical issues restrict their applications in AD. Recently, the direct reprogramming of induced neural progenitor cells (iNPCs) has shed light on the treatment of AD. In this review, we will discuss the latest progress, challenges, and potential applications of direct reprogramming in AD treatment.

KW - Alzheimer's disease

KW - Induced neural progenitor cells

KW - Stem cell-based therapy

UR - https://www.scopus.com/pages/publications/84928821804

UR - https://www.scopus.com/pages/publications/84928821804#tab=citedBy

U2 - 10.1186/s40035-015-0028-y

DO - 10.1186/s40035-015-0028-y

M3 - Review article

AN - SCOPUS:84928821804

VL - 4

JO - Translational Neurodegeneration

JF - Translational Neurodegeneration

IS - 1

M1 - 7

ER -

Direct reprogramming of induced neural progenitors: A new promising strategy for AD treatment

Abstract

Bibliographical note

Funding

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this